Abstract Prion infections of the central nervous system (CNS) are characterized by initial reactive gliosis followed by overt neuronal death. Gliosis is likely to be caused initially by the deposition of misfolded, proteinase K-resistant, isoforms (termed PrP Sc ) of the normal cellular prion protein (PrP c ) in the brain. Proinflammatory cytokines and chemokines released by PrP Sc -activated glia and stressed neurons may also contribute directly or indirectly to the disease development by enhancing gliosis and inducing neurotoxicity. Recent studies have illustrated that early neuroinflammation activates nuclear factor of activated T cells (NFAT) in the calcineurin signaling cascade, resulting in nuclear translocation of nuclear factor kappa B (NF-κB) to promote apoptosis. Hence, useful therapeutic approaches to slow down the course of prion disease development should control early inflammatory responses to suppress NFAT signaling. Here we used a hamster model of prion diseases to test, for the first time, the neuroprotective and NFATsuppressive effect of a second-generation semisynthetic tetracycline derivative, minocycline, versus a calcineurin inhibitor, FK506, with known NFAT suppressive activity. Our results indicate that prolonged treatment with minocycline, starting from the presymptomatic stage of prion disease was more effective than FK506 given either during the presymptomatic or symptomatic stage of prion disease. Specifically, minocycline treatment reduced the expression of the astrocyte activation marker glial fibrillary acidic protein and of the microglial activation marker ionized calcium-binding adapter molecule-1, subsequently reducing the level of proinflammatory cytokines interleukin 1β and tumor necrosis factor-α. We further found that minocycline and FK506 treatment inhibited mitogenactivated protein kinase p38 phosphorylation and NF-κB nuclear translocation in a caspase-dependent manner, and enhanced phosphorylated cyclic adenosine monophosphate response element-binding protein and phosphorylated Bcl2-associated death promoter levels to reduce cognitive impairment and apoptosis. Taken together, our results indicate that minocycline is a better choice for prolonged use in prion diseases and encourage its further clinical development as a possible treatment for this disease.
Introduction
Scheinker syndrome, and fatal familial insomnia in humans [1, 2] . Prion diseases have been the object of growing interest since the discovery of the newest, most devastating form of TSEs in humans, termed variant CJD [3] . Prion diseases are characterized by the presence of PrP Sc , an abnormal proteaseresistant misfolded isoform of the cellular prion protein PrP c [3, 4] . PrP Sc is highly pathogenic and neurotoxic owing to its β-sheet-rich conformation as compared with the predominantly α-sheet-rich structure of PrP c [5, 6] . Like several other neurodegenerative disorders, prion diseases are also associated with the accumulation and aggregation of misfolded/ unfolded disease-specific proteins in the brain, leading to neuroinflammation and neurodegeneration. However, the exact molecular mechanisms behind neuronal inflammation and apoptosis are still unclear, and hence the development of an effective therapeutic strategy remains elusive [7] .
T-cell activation contributes to disease pathogenesis by creating an inflammatory environment that leads to cellular damage and, ultimately, to cell death, as well as decreased immune function. Activated T cells increase neuroinflammation by activating microglia and, subsequently, the nuclear factor of activated T cells (NFAT) signaling cascade, leading to nuclear translocation of nuclear factor kappa B (NF-κB) [8] . Given its function as a key regulatory factor in T-cell activation, NFAT is 1 of the major targets of traditional immunosuppressive drugs in the immunophilin ligand class (ciclosporin A, FK506) [9] . Recently, modulation of T-cell activation and function has been proposed as 1 of the major mechanisms of action of nontraditional immunosuppressive drugs towards achieving the goal of reducing neuroinflammation and alleviating neurodegeneration.
Minocycline, a tetracycline derivative, is well known for its antimicrobial properties in many bacterial infections; however, the cytoprotective role mediated by minocycline is still unclear. Minocycline is broadly protective in neurologic disease models featuring inflammation and cell death, and is being evaluated in clinical trials of major neurodegenerative diseases or brain injury models [10] [11] [12] [13] [14] [15] . Microglia, the brain innate immune macrophage-like cells, are activated by the oligomers and fibrils formed by amyloid proteins, including PrP Sc , and are normally found clustered around amyloid plaques where they phagocytize and degrade plaques as an integral part of clearance mechanism [13] . The activation states of microglia are divided into 2 distinct phenotypes based on their relationship with inflammatory processes: M1 (proinflammatory phenotype) and M2 (anti-inflammatory phenotype). M1 microglia release proinflammatory and neurotoxic molecules that contribute towards cell death, whereas M2 microglia release anti-inflammatory molecules, including cytokines and neurotrophic factors that help in nervous system repair and regeneration processes [13, 16] . T cells are postulated to be a primary target of minocycline, involving the suppression of NFAT signaling leading to reduced NF-κB nuclear translocation in CD + T cells, as recently reported [8] . Tacrolimus or FK506 is a well-known immunosuppressive drug, mainly used to combat allograft rejection in solid-organ transplant recipients. FK506 binds to the FK506-binding protein (FKBP) and the FK506/FKBP complex interacts with and inhibit calcineurin (CaN), a calcium-and calmodulindependent phosphatase, resulting in the inhibition of NFAT and thus suppression of the T-lymphocyte-mediated signal transduction pathway leading to interleukin (IL)-2 transcription [17] . Notably, FK506 has also been reported to afford neuroprotection in various animal models of central nervous system (CNS) injury [18] [19] [20] , as well as several neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease, and prion diseases [1, 3, [21] [22] [23] .
A novel therapeutic strategy towards achieving the goal of neuroprotection in neurodegenerative diseases should be focused on modulating microglial activity to promote their neuroprotective mechanisms and alleviate their neurotoxic mechanisms in early stages of neurodegeneration. With this goal in mind, the present study was designed to evaluate the neurotherapeutic efficacy of minocycline and FK506 in an animal model of prion diseases. Specifically, we explored the comparative immunomodulatory effect of minocycline and FK506 at a cellular level on the expression of different cell populations in the brain of prion-infected hamsters and evaluated their effect on prion-related cognitive impairments and survival.
Materials and Methods

Animal Ethics Statement
All experimental procedures with the laboratory animals used in this study were performed and approved according to the strict guidelines of Chinese Regulations of Laboratory Animals-The Guidelines for the Care of Laboratory Animals (Ministry of Science and Technology of People's Republic of China), and Laboratory Animal Requirements of Environment and Housing Facilities (GB 14925-2010, National Laboratory Animal Standardization Technical Committee). The license number related to the research protocol was 20110611-01, and the animal study proposal was approved by The Laboratory Animal Ethical Committee of China Agricultural University, Beijing, China. We aimed to minimize the suffering of the animals and to reduce the number of animals studied at minimum.
Animal Model of Prion Diseases
The infectious model of prion disease in hamsters is a very good model for TSE-related studies, as it reproduces many of the clinical, neuropathologic, and biochemical aspects of the disease in humans and other mammals in a relatively short incubation period as compared with other animal models [24] . Five-week-old Syrian golden hamsters (n = 60) were used in the current study. Each animal was housed in a separate cage. The animals were divided randomly into 5 groups: prion-vehicle group administered with 0.9% saline as a positive control group with only vehicle treatment once daily started at day 65 postinfection before the appearance of obvious clinical signs (group A); prion-FK506 early treatment started at day 65 postinfection with once-daily injection of FK506 before the appearance of obvious clinical signs (group B); prion-FK506 late treatment started at day 90 postinfection with once-daily injection of FK506, when the first visible signs of disease were observed in more than half of the animals (group C); prion-minocycline treatment started at day 65 postinfection with once-daily injection of minocycline before the appearance of obvious clinical signs (group D); and no prion-vehicle group administered with 0.9% saline as negative control group with only vehicle treatment given once daily on a daily basis (group E). All groups consisted of 12 animals. Normal saline (0.9%) was used a vehicle treatment in groups A-E to induce same level of stress in infected and noninfected animals. All the animals except those in group E were injected intraperitoneally (i.p) with 75 μl 10% brain homogenate prepared in phosphate buffered saline from terminally dead hamsters with 263 K strain of prion according to previous protocols [25, 26] . The animals showed first sign of disease after 80 ± 10 days postinfection. The signs were divided into 5 stages: 1) normal animal; 2) roughcoat on limbs with erect hairs; 3) extensive roughcoat, hunckback, circling, and visible motor abnormalities; 4) urogenital lesions; and 5) terminal stage of the disease in which the animal presented with cachexia and lies in the cage with little movement. The period between the appearance of the first disease symptom and death range between 10 to 30 days in animals without treatment. Treatment administration of FK506 and minocycline was carried out until animals died or were sacrificed for experiment.
FK506 Preparation and Administration
FK506 (Cat# F-4900) was purchased as white crystalline powder from LC Laboratories (Woburn, MA, USA). Purity was ≥ 99%. F506 stock solution (0.5 mg/ml) was prepared by dissolving the compound in saline (0.9% NaCl) containing 1.25% PEG40 Castor Oil (Cat#C9510; Solarbio Life Sciences China, Beijing, China), and 2% ethanol (Beijing Chemical Works, Beijing, China). Animals in group B and C were injected i.p. with 0.12 mg FK506 (5 mg/kg) dissolved in 100 ml of the vehicle solution mentioned above [3] . FK506 stock solution was stored frozen in a light-protected bottle.
Minocycline Preparation and Administration
Minocycline (M9511) was purchased as yellow crystalline powder from Sigma-Aldrich (St. Louis, MO, USA). Purity was ≥ 99%. Minocycline stock solution (0.5 mg/ml) was prepared by dissolving the compound in saline (0.9% NaCl) containing 1.25% PEG40 Castor Oil (Cat#C9510; Solarbio Life Sciences China) and 2% ethanol (Beijing Chemical Works). Animals in group D were injected i.p. with 0.36 mg minocycline (15 mg/kg) dissolved in 100 ml of the vehicle solution mentioned above according to previous experiments [27] [28] [29] . Minocycline stock solution was stored frozen in a light-protected bottle.
Reagents
The rabbit polyclonal anti-pan-CaN A antibody (2614; 1:1000; Cell Signaling Technology, Danvers, MA, USA). The rabbit polyclonal anti-CaN B antibody (AF1348; 0.25 μg/ml; R&D Systems, Minneapolis, MN, USA).The rabbit polyclonal antiBcl2-associated death promoter (BAD) antibody (9292; 1:1000), rabbit polyclonal antiphosphor-BAD antibody (9291; 1:1000), rabbit monoclonal anti-cyclic adenosine monophosphate response element-binding (CREB) antibody (9197; 1:1000), rabbit monoclonal antiphospho-CREB antibody (9198; 1:1000), rabbit polyclonal anti-p38 mitogen-activated protein kinase (MAPK) antibody (9212; 1:1000), rabbit polyclonal antiphospho-p38 MAPK antibody (9211; 1:1000), and rabbit polyclonal antinucleophosmin antibody (3542; 1:1000) were purchased from Cell Signaling Technology. The rabbit polyclonal anticaspase-12 antibody (55238-1-AP; 1:2000), rabbit polyclonal anticaspase-9 antibody (10380-1-AP; 1:2000), rabbit polyclonal anticaspase-3 p17-specific antibody (25546-1-AP; 1:1000), rabbit polyclonal anti-postsynaptic density protein 95 antibody (20665-1-AP; 1:800 Western Blot), rabbit polyclonal antisynaptophysin antibody (17785-1-AP; 1:800 WB), rabbit polyclonal p65, RELA antibody [10745-1-AP; 1:2000 WB (1:50 Immunohistochemistry)], rabbit polyclonal anti-glial fibrillary acidic protein (GFAP) antibody (16825-1-AP; 1: 50 IHC), rabbit polyclonal anti-NeuN antibody (23060-1-AP; 1:50 IHC), and rabbit polyclonal anti-ionized calcium-binding adapter molecule 1 (IBA-1) antibody (10904-1-AP; 1:50 IHC) were purchased from Proteintech Biotechnology (Chicago, IL, USA). The rabbit polyclonal antilamin A/C antibody (D120927; 1:50 IHC) was from BBI Life Sciences (Sangon Biotechnology, Shanghai, China). The mouse monoclonal antiprion-3 F4 antibody (SIG-39600; 1:1000; SIGNETCovance, San Diego, CA, USA). The rabbit polyclonal β-tubulin antibody (10094-1-AP; 1:5000) and mouse monoclonal antiglyceraldehyde 3-phosphate dehydrogenase antibody (60004-1-lg; 1:1000) were from Proteintech Biotechnology. The rabbit polyclonal antirat β-actin antibody (Cat#AP0060; 1:1000) and goat antirabbit IgG (Heavy and Light Chains)-horseradish peroxidase (HRP) secondary antibody (Cat#BS13278; 1:5000) were purchased from Bioworld Technology (Nanjing, China). The rabbit antigoat IgG (H+L) (ZB-2306; 1:5000), Alexa Fluor 594-Conjugated AffiniPure Goat Anti-Rabbit IgG (H&L) (ZF-0516; 1:100), and goat antimouse IgG (H&L)-HRP secondary antibody (1:100) were purchased from Beijing ZSGB Biotechnology (Beijing, China). 4,6-Diamidino-phenylindole dihydrochloride and propidium iodide were purchased from Beyotime Biotechnology (Wuhan, China). DAB Horseradish Peroxidase Color Development Kit (P0202) (Beyotime Biotechnology). Reagents and apparatus used in immunoblotting assays were purchased from Bio-Rad (Richmond, CA, USA). The Colorimetric Mouse TNF-α ELISA kit (KE10002;) was from Proteintech. The IL-1 beta/IL-1 F2 ELISA kit (DY401-05) was from R&D Systems.
CaN Activity Assay
The phosphatase activity of CaN was measured using the Calcineurin Cellular Activity Assay kit (Cat#207007; Calbiochem, Darmstadt, Germany) as previously described [3] . The brain homogenates were prepared in the assay buffer and the residual phosphate was removed by passing through a desalting column. A final concentration of 1 μg/μl of the homogenate was used for the enzyme assay in presence of bovine calmodulin. The reaction mixture was incubated with a final concentration of 150 mM RII peptide (substrate) at 37°C for 20 min and reactions were terminated by the addition of 100 ml malachite green reagent. Product formation was measured by recording the absorbance at 635 nm.
Animal Behavioral Studies
To investigate whether treatment with minocycline and FK506 alters clinical signs, we performed nesting behavior; open field; and novel object recognition tests. The nesting behavior was observed continuously for 13 weeks and scoring in a group was done according to a previous protocol, with little modification [30] . Briefly, partially shredded colored paper was placed on the opposite side of the normal nesting location within the cage, and nesting was scored the next day on the basis of the location of the shredded paper inside or near the nest. The quality of the nests was evaluated using a modified 5-point scale. Tissue not noticeably touched, moved, or shredded (>90% in same place as originally placed = 1 point); tissue partially touched, moved, or shredded (50-90% near the nest or inside nest = 2 points); mostly shredded or moved but not identifiable as a nest (>50% of the paper near the nest or inside the nest = 3 points), an almost intact nest (>90% of the paper near or inside the nest = 4 points); an intact nest (100% of the paper inside the nest = 5 points). Openfield tests were performed to monitor exploratory behavior and locomotor activity according to a previous experiment with a little modification [31] . Briefly, the animals were placed individually at the center of a 100 × 100 × 40-cm wooden box and left to move freely within it for 5 min. For all behavioral tests, data were gathered with a digital video camera (Sony W280) mounted on top of the open-field box. The box was divided into 15 equal horizontal and vertical lines and all activities during various time intervals were recorded. We measured and analyzed total distance covered, moving time, inactive time, and rearing activity time in 5-min test intervals. Testing was carried out in a temperature, noise, and light controlled room.
Novel object recognition tests were performed a day after the open-field test in a 100 × 100 × 40-cm wooden box [32] . Animals were pretrained to habituate to the box for 2 consecutive days, without objects present. For testing, animals were placed individually at the inlet made in side wall the of the box and the central part of the box was covered with different color paper each time to attract hamsters to the presence of 4 objects of 2 identical shapes (old objects) for 10 min. The identically shapes objects were placed side by side before the test. After that period, the box and objects were cleaned with 50% methanol solution. The animal was later (after 2 h) exposed to the identical objects placed across from each other and in center a dummy sheep was placed as a novel object, and the box and objects were cleaned again to continue with the next animal. The recognition index was calculated as the time spent exploring the new object divided by the time exploring old objects.
PrP
Sc Detection Assay
The presence and quantity of PrP Sc in brain homogenates of sick animals was measured by a standard assay consisting of the ability of the misfolded protein to resist proteolytic degradation. Samples were incubated in the presence of proteinase K (50 μg/ml) for 1 h with shaking at 37°C. The digestion was stopped by adding electrophoresis sample buffer and proteaseresistant PrP Sc was detected by Western blotting, as previously described [24] . Briefly, proteins were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), electroblotted onto polyvinylidene fluoride membranes (Immobilon-PSQ, ISEQ00010, 0.2 μm). Blots were blocked by 5% nonfat milk in TBST (25 mMTris base, 137 mM sodium chloride, 2.7 mM potassium chloride and 0.05% Tween-20; pH7.4) for 1 h at room temperature, incubated with the indicated 3 F4 antibody at 4°C overnight and the corresponding HRP-labeled secondary antibody for 50 min at 37°C, and the signal detected using an enhanced chemiluminescence detection kit (Bio-Rad, Hercules, CA, USA).
Western Blotting
Frozen brain samples were homogenized in RIPA buffer containing a cocktail of protease inhibitors and were sonicated for 15 s, and then centrifuged at 20,000 × g for 5 min. The supernatants were collected and boiled for 10 min after addition of loading buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 0.5 % Bromop henol Blue, 50 % glycero l, 0.5 M Dithiothreitol). Protein concentration in each sample was measured before adding loading buffer by using a Bicinchoninic Acid Assay (BCA) (CWBio, Shanghai, China) and 40 μg/well of protein extracts were subjected to SDS-PAGE, and Western blotting. Samples for PrP Sc detections and other sample aliquots were separated via SDS-PAGE and the proteins were transferred to polyvinylidene fluoride membranes (Immobilon-PSQ, ISEQ00010, 0.2 μm). Blots were blocked by 5% nonfat milk in TBST (25 mMTris base, 137 mM sodium chloride, 2.7 mM potassium chloride and 0.05% Tween-20; pH 7.4) for 1 h at room temperature, incubated with the indicated primary antibody overnight at 4°C and the corresponding HRP-labeled secondary antibody for 50 min at 37°C, and the signal detected using an enhanced chemiluminescence detection kit (Bio-Rad).
Tissue Preparation and Immunohistochemistry Analysis
Histological studies were carried out to assess the effect of FK506 and minocycline treatment on brain damage. Brains from dead or sacrificed animal were removed surgically under aseptic conditions as quickly as possible. Terminally sick animals showing the 5 signs on the scale were anaesthetized with ketamine:zyline 3:1 (250 μl/100 g body weight); then whole brain was excised aseptically and cut sagitally into 2 halves-1 half was snap frozen in liquid nitrogen for Western blot and CaN assay, while the other half was fixed in 10% formaldehyde solution, embedded in paraffin, and cut into sections using a microtome (Leica RM2235; Leica, Buffalo Grove, IL, USA). Serial sections (from 2 μm to 5 μm thick) from each block were stained to assess spongiform degeneration, brain inflammation, neuronal degeneration, and neuronal loss. The following studies were done.
Brain Vacuolation
One of the neuropathologic hallmarks of prion diseases is the presence of spongiform degeneration in the brain. Vacuolation was assayed by staining of the tissue with hematoxylin and eosin. Then, the numbers of vacuoles were counted and scored on a scale from 1 to 4 in cerebellum, medulla, hippocampus thalamus, and cortex of each animal, as described [33] .
Brain Inflammation
Astrocytosis was assessed by immunohistochemistry techniques utilizing antibodies against GFAP expressed in abundance in activated astrocytes, following a previously described protocol [33] . Staining for activated microglia was done with the IBA-1 antibody. IBA-1 is a 17-kDa interferon-γ-inducible calcium-binding protein, associated with chronic inflammatory processes, which has been previously used to assess microglial activation in patients with CJD [34] . Digital images were collected on Olympus DP72 microscope fitted with an apotome for optimal sectioning. To calculate the extent of astrocytosis and microglial activation, 5 brains from each group were visualized at 10×, 20×, and 40×. All the brain regions were carefully visualized and the stained area compared with the total tissue area was determined by using the Image-Pro Plus 6 program (Media Cybernetics, Rockville, MD, USA).
Neurodegeneration
To evaluate neuronal degeneration and death we used FluoroJade C (23062; AAT Bioquest, Sunnyvale, Canada) staining to detect degenerated cells and NeuN, a specific marker for neurons, was used for immunohistochemistry analysis of living neurons. The Fluoro-Jade C staining was done following the protocol described by Schmued [35] . Briefly, 5-μm sections were cut from paraffin-embedded brains and spread on microscope slides and allowed to air dry, followed by mounting on microscope slides and placed in 70% ethanol. The sections were washed and oxidized by soaking in a solution of 0.06% KMnO 4 for 15 min. After washing, they were stained with 0.001% FluoroJade C (AAT Bioquest) in 0.1% acetic acid for 20 min. Slides were washed again and dried overnight at room temperature. Digital images were collected on an Olympus Fluoview FV1000 confocal microscope. Five 20× sections of cerebellum, medulla, thalamus, and cortex were collected per animal. FluoroJade C-positive cells were counted from each field. The number of total neurons was counted after staining with the polyclonal anti-NeuN antibody (Proteintech) at 1:100 dilutions. NeuN is a specific neuronal marker for a DNA-binding protein present in the nucleus of postmitotic neurons [36] . Brain sections were mounted onto gelatin-coated coverslips and allowed to air dry. Air-dried sections were blocked and permeabilized in 0.1 Molar Phosphate Buffered Solution (M PB) with 0.3% TX-100 (Sigma-Aldrich) and 10% fetal calf serum for 1 h. Following permeabilization, the mouse polyclonal anti-NeuN antibody (Proteintech) was applied at a 1:100 dilution and incubated overnight at room temperature. After washing, the secondary antibody was applied for 1 h at 37°C followed by 3 consecutive washes and color development via 3, 3'-Diaminobenzidine (DAB) application. Slides were visualized under the microscope by 2 different researchers blinded to the treatment, who counted the number of neurons in different brain areas.
Preparation of the Cytoplasmic and Nuclear Extracts
The brain tissue was homogenized with ice-cold PBS buffer using a dounce homogenizer until a clear suspension was visible with the naked eye; it was then centrifuged at 500 × g for 2 to 3 min. A cyctoplasmic and nuclear protein extraction kit (AR0106; Boster Biological Technology, Pleasanton, Canada) was used to prepare cytoplasmic and nuclear extracts. The supernatant was removed and the sediment volume was estimated. The sedimentary cells were resuspended in 1:10 of cytoplasmic extraction reagent, shaken and vortexed strongly for 15 s until the cell sediment was mixed with cytoplasmic extraction reagent and incubated for 10 to 30 min on ice, shaken at high speed for 5 s, centrifuged at 12,000 to 16,000 × g for 10 min at 4°C. The supernatant was pipetted into precooled plastic tubes; the supernatant obtained was used as cytoplasmic extract. The sediment was suspended in a 1:2 ratio of nuclear extraction reagent. High-speed shaking was done for 15 s until the sediment mixed completely with nuclear extraction reagent. Then the sample was incubated in an ice bath for 30 min. Then samples were shaken at high speed for 10 to 20 s, centrifuged at 12,000 to 16,000 × g for 10 min at 4°C. The supernatant was pipetted into precooled plastic tubes and the supernatant contained nuclear protein.
Statistical Analysis
All assays were performed on 3 separate occasions. Data are expressed as means ± SD. All comparisons for parametric data were made using 1-way analysis of variance followed by post-hoc Turkey's multiple comparison test or 2-way analysis of variance followed by post-hoc Bonferroni multiple comparison test using the GraphPad Prism 5 software (GraphPad, La Jolla, CA, USA) The in vivo survival study was assessed with the log-rank (Mantel-Cox) test using GraphPad Prism 5 and ImagePro Plus (Media Cybernetics, Rockville, MD, USA) was used for immunohistochemistry image analysis. A p-value < 0.05 was considered statistically significant.
Results
Minocycline-Enhanced Nesting Behavior, Locomotor Function, Novel Object Finding, and Prolonged Survival in Prion-Infected Hamsters
The nesting habit, exploratory behavior, and general locomotor activity are widely used tools in rodent behavioral science, where both the quality and quantity of the activity can be measured. To assess the effect of minocycline and FK506 on the nesting behavior of Syrian golden hamsters, we checked the nest quality of all experimental groups once weekly for 13 weeks until the appearance of clinical signs. Scoring of the nesting behavior was as previously described [30] , with minor modifications. Briefly, shreddings of sheets of paper of various colors were placed in the animal cage and after 24 hours the nest quality and the presence of shredded paper in or around the nest was checked. The results showed that in the first 2 months of the study, there was no significant difference in the nesting behavior among any of the experimental groups, except the prion-vehicle group (group A) and no prion-vehicle group (group E; Fig. 1a, b) . However, during the last 2 weeks of the third month, the nesting behavior of the prion-vehicle (group A) and prion-FK506 (group B) group was dramatically reduced as the disease progressed, while the prion-minocycline group (group D) had intact nesting behavior throughout the 13-week trial period and beyond (Fig. 1a, b) . To investigate the locomotor and novel object exploring behavior, each animal was individually placed into an open-field test arena and observed for 5 min. Our results showed that there was no Fig. 1 Minocycline-enhanced nesting behavior, locomotor function, novel object finding, and prolonged survival in prion infected hamsters. (a) Representative pictures of the nesting behavior observed in prioninfected and noninfected groups; top panel shows the nesting plan, where colored shredded paper was placed in top portion of the cage, while the bottom four images show the nesting behavior when the shredded paper was moved to or near the nest after overnight exposure. (b) Nesting score based on nest quality and movement of shredded paper from its initial location. The graph represents the data of 3 animals per group. Data were analyzed by 2-way analysis of variance (ANOVA) with Bonferroni's post-test (***p < 0.001). (c) Graph shows moving, inactive, rearing activity, and novel object exploration duration in experimental groups relative to 5-min test time; number of animals tested per group was 5. Data were analyzed by 2-way ANOVA with Bonferroni's post-test (***p < 0.001). (D) Total distance covered relative to 5-min test time in experimental groups; number of animal tested per group was 5. Data were analyzed using 1-way ANOVA with Tukey's multiple comparison posttest (***p < 0.0001). (E) Survival analysis in different groups using the log-rank (Mantel-Cox test); each group comprised 12 animals. (F) Graph showing the infective period in all the groups. The number of animals per group used for statistical analysis was 12 and the data were analyzed by 1-way ANOVA test with Tukey's multiple comparison post-test (***p < 0.0001). ns = nonsignificant significant difference between groups over the first 2 months postinfection. There was no significant difference in moving and inactive times during the third month of testing period, while a significant difference was observed in rearing and novel object exploring times in the prion-minocycline (group D) and prion-FK506 group (group B; Fig. 1c ; Videos S1-S8). To further investigate locomotor function, we measured the total distance covered by individual animals during the 5-min test period. We found a significant difference in total distance covered between the prion-minocycline group (group D) and prion-FK506 group (group B; Fig. 1d ). The life expectancy measurement is a reliable indicator of the efficacy of any therapeutic drug. Our results showed that the prion-minocycline group (group D) had significantly prolonged survival compared with all other prion-infected groups, including prion-FK506 early treatment at 65 days (group B) or prion-FK506 late treatment started at 85 days postinfection (group C; Fig. 1e ). We further confirmed that prion-FK506 late treatment was more effective than prion-FK506 early treatment (Fig. 1e, f) . The health status of an animal can be judged by assessing daily weight gain and feed and water consumption. Our results showed that the weight of animals in all experimental groups increased until week 9, followed by a decline after week 10 postinfection (Fig. S1A) . A more pronounced weight loss was observed in the prion-FK506 group (group B), followed by the prion-vehicle group (group A) and prion-minocycline group (group D) respectively (Fig. S1A) . We further confirmed that the loss of animal body weight was directly proportional to feed and water consumption, which underwent a sudden decline after week 10 of infection except in the no prion-vehicle group (group E), which consumed amount of food and water proportionate with recorded increase in animals weight (Fig. S1B, C) .
Minocycline Partially Reduced the Activation of CaN in Prion-Infected Hamsters
Accumulation of misfolded proteins in the endoplasmic reticulum (ER), leading to dysregulated calcium Fig. 1 (continued) homeostasis is observed in all protein misfolding neurodegenerative diseases [37, 38] . To investigate whether hyperactivation of CaN is dependent on the level of PrP Sc in the brain homogenates obtained from the different group of animals, brain homogenates were treated with Proteinase K (PK) (50 μg/ml for 1 h at 37°C) and evaluated by Western blot. We found no difference in the level of PrP Sc in any of the infected groups of hamsters (Fig. 2a) . These data suggest that minocycline and FK506 act downstream to PrP Sc aggregation and have no effect on misfolding of prion. Cytoplasmic calcium concentrations modulate CaN activity after the accumulation of misfolded proteins [3] . We checked CaN activity at 2 different time points in our experimental model of prion disease, on day 85 postinfection, just before the appearance of first visible clinical signs, and on day 125 of infection. Our results showed that CaN activity was significantly elevated in the prion-vehicle group (group A) compared with other groups (Fig. 2b) , and that CaN levels further increased with the progression of disease. Notably, there was no increase in CaN activity in the prion-minocycline group (group D), suggesting partial reduction in misfolded PrP Sc and reduced neuroinflammation in this group of animals (Fig. 2b) . (Fig. 2c-f) . 
Minocycline Efficiently Reduced Astroglyosis in Prion-Infected Hamsters
To assess the effect of minocycline on prion-induced neurodegeneration, formalin-fixed, paraffin-embedded brain sections from 5 animals per group were stained and analyzed. Spongiform degeneration, brain vacuolation, and astroglyosis are hallmarks of prion diseases [39] . Accordingly, the medulla, cerebellum, thalamus, and cortex were analyzed for astrocytes and microglial activation. There was a highly significant difference in astrocytes activation in prion-infected groups compared with noninfected groups (Fig. 3a, b) . The prion-vehicle group (group A) showed the most astrocytes activation in all 4 observed regions of brain, while cerebellum, thalamus, and cortex of prion-minocycline (group D) and prion-FK506 late (group C) had less activated astrocytes than prion-vehicle (group A) and prion-FK506 early (group C) treatment (Fig. 3a, b) , suggesting that although both drugs reduced number of astrocytes in the prion-infected animals, the reduction was partial compared with animals in the no prion-vehicle group (group E) that had almost no activated astrocytes.
Microglia, the resident immune cells of the CNS, play an important role in CNS homeostasis during development, adulthood, and aging. Microglial function is tightly regulated by the CNS microenvironment, and increasing evidence suggests that disturbances, such as neurodegeneration and aging, can have profound consequences for microglial phenotype and function [40] . We observed in all 4 brain regions that microglial activation was significantly reduced in the prionminocycline group (group D)and prion-FK506 late group (Fig. 3c, d) , suggesting an effect of drug treatment on prion-driven microglial activation.
Minocycline Rescues Prion-Infected Hamsters From Spongiform Degeneration
Spongiform degeneration and brain vacuolations are the hallmarks of prion infection [39] . We observed vacuolations mostly in medulla and cerebellum of prion-infected animals (Fig. 4a, b) . Our results showed a significantly higher number of vacuoles in the medulla of the prion-vehicle group (group A) and, to a minor extent, in the prion-FK506 late treated group (group C), whereas the prion-FK506 early (group B) and prion-minocycline (group D) groups had significantly less vacuolation (Fig. 4a) . The number of vacuoles in cerebellum was also higher in the prion-vehicle (group A) and prion-FK506 late (group C) groups, but noticeably less in the prion-FK506 early (group B) and the prion-minocycline group (group D) animals. Less vacuolation was observed in thalamus of the prion-minocycline group (group A), with no significant difference in vacuolation profiles of cortex in all infected hamsters (Fig. 4a, b) . These data suggest that minocycline and FK506 treatment administered during the presymptomatic stage of prion disease significantly reduce brain vacuolation compared with FK506 treatment started after the insurgence of the clinical symptoms of the disease.
Minocycline Rescues Prion-Infected Hamsters From Synaptic Dysfunction and Neurodegeneration
Excessive activation of CaN in neurons results in early, reversible impairment and late, irreversible cell damage. Consequently, reversal of neuronal injury is only possible in the early stages of disease. If treatment is delayed, proapoptotic Bcl-2 family proteins are activated, leading to apoptosis and neurodegeneration [3, 4] . Sustained long-term ER stress leads to early neurodegenerative anomalies such as synaptic dysfunction and hampered axonal transport, which are followed by neuronal death [41, 42] . To study the number of CNS neurons in our experimental conditions, we fixed 5 brains from each group and immunohistochemical analysis was performed using the well-established neuronal marker NeuN [36] . Our results in the thalamus region showed a significantly higher number of neurons in prion-minocycline group (group D) and prion-FK506 late group (group C) as compared with other infected groups (Fig. 5a) . Indeed, hamsters in the prion-minocycline group (group D), and prion-FK506 late treatment group (group C) had almost double the number of neurons as compared with prion-vehicle group (group A) animals (Fig. 5a, b) , suggesting that treatment with minocycline in the presymptomatic stage or with FK506 after the appearance of first visible signs of prion infection is more effective than FK506 given early, before the appearance of clinical symptoms. Although our neuron analysis shows a significantly higher number of neurons in the prionminocycline group (group D) and prion-FK506 late group (group C); however, the number of neurons was significantly less than in the no prion-vehicle group (group E) animals, suggesting partial protection with minocycline and FK506 treatment (Fig. 5b) .
In order to further characterize neuronal damage in our experimental groups, we used a well-established method to stain the brain sections with Fluoro-Jade, which specifically stains degenerating neurons [35] . In the thalamus, we observed a significantly lower number of Fluoro-Jade-positive cells in the prion-minocycline (group D) and prion-FK506 late (group C) groups compared with other infected groups (Fig. 5c, d) . However, the efficacy of the treatments was moderate as the number of Fluoro-Jade-positive cells remained significantly higher in all of the prion-infected groups compared with the noninfected vehicle group (group E; Fig. 5d) .
To evaluate the effect of our treatments on synaptic dysfunction we carried out Western blot analysis for the synaptic proteins postsynaptic density protein-95 and synaptophysin in the brain homogenates. Our results suggest a significant protection of synaptic proteins with minocycline treatment followed by FK506 treatment in prion-infected hamsters (Fig. 5e, f) .
Minocycline Modulates the Caspase-Dependent MAPK Pathway
While the exact molecular mechanisms leading to neurodegeneration in protein misfolding disorders, including prion disease, are still unclear, compelling evidence suggests that 1 event that appears to be common to all neurodegenerative disorders is early neuroinflammation that contributes towards later neurodegeneration [7, 13, 43] . Stimulated microglia release several proinflammatory and neurotoxic molecules, including tumor necrosis factor (TNF)-α, IL-1β, IL-6, nitric oxide, eicosanoids, proteinases, and reactive oxygen species [44, 45] . To assess the effect of minocycline treatment on neuroinflammation, we determined the levels of IL-1β and TNF-α in brain homogenates of prion-infected hamsters. We observed a significant increase in IL-1β and TNF-α levels in infected hamsters compared with noninfected animals; however, prion-minocycline animals (group D) had significantly lower IL-1β levels and TNF-α levels compared with prion-FK506 early (group B) and prion-FK506 late animals (group C; Fig. 6a) . Notably, IL-1β levels in the prion-minocycline group (group D) were not significantly different from those of the uninfected control animals, whereas TNF-α levels were only slightly, albeit significantly increased (Fig. 6b) . These data suggest that minocycline effectively reduced proinflammatory cytokines levels in the brain of prion-infected hamsters compared with FK506 treatment.
Activated microglial cells control the release of proinflammatory mediators through activation of the MAPK signaling pathways [46] . To gain a better insight into the molecular mechanisms mediating the beneficial effects of minocycline and FK506, we therefore determined the level of total MAPK p38 and MAPK phosphorylated p38 in brain homogenates from our experimental groups. Our results showed a significant difference in phosphorylated MAPK p38 level between prion-vehicle (group A) and prion treatment groups (groups B-D); furthermore, animals in the prion-FK506 early treatment group (group B) had significantly higher expression of phosphorylated MAPK p38 compared with those in the prion-FK506 group (group C), whereas animals in the prionminocycline group (group D) and the no prion-vehicle group (group A) showed further reduced expression of phosphorylated MAPK p38 (Fig. 6c, d) , suggesting that treatment with minocycline in the presymptomatic stage and with FK506 in the symptomatic stage of the prion infection were more effective than FK506 treatment administered during the presymptomatic stage of prion disease.
Compelling evidence suggests that aggregation of misfolded/unfolded proteins leads to ER stress and a subsequent increase in cytoplasmic Ca 2+ followed by Ca 2+ uptake by mitochondria, resulting in cytosolic cyctochrome C release, triggering activation of caspases, and resulting in apoptotic cell death [47] [48] [49] [50] . To investigate whether phosphorylated MAPK p38 triggers caspase- mediated apoptotic cell death in response to prion infection and the effect of minocycline and FK506, we determined caspase-12, caspase-9, and caspase-3 levels in the brain homogenates from all of the experimental groups. We observed significantly higher levels of caspase-12, caspase-9, and caspase-3 activation in the prion-vehicle group (group A) compared with all other groups of animals (Fig. 6e, f) . These data suggest that a caspasemediated phosphorylated MAPK p38 pathway mediates neurodegeneration induced by prion, and this phenomenon was significantly reduced by minocycline and FK506 treatment.
Minocycline Effectively Leads to Reduced NF-κB p65 Nuclear Translocation MAPK phosphorylation result in translocation of NF-κB from cytoplasm to nucleus. NF-κB transcription factors are present in the cytosol in an inactive state complexed with inhibitory kappa B proteins. MAPK phosphorylation leads to phosphorylative activation of inhibitory kappa B and its subsequent proteosome-mediated degradation, resulting in the release and nuclear translocation of active NF-κB [44, 51] . To determine the nuclear translocation of NF-κB we prepared cyctoplasmic and nuclear extract from brain homogenates of all experimental groups and subjected them to Western blot analysis. We found increased NF-κB levels in the nuclear fraction of prionvehicle group (group A) compared with all of the other groups of animals (Fig. 7a, b) . Furthermore prionminocycline (group D) and prion-FK506 (groups B and C) animals had almost twice the levels of NF-κB in the cyctoplasm than prion-vehicle animals (group A), similar to the levels found in the no prion-vehicle group (group E). These results indicate that minocycline and FK506 significantly reduced activation of NF-κB, and its subsequent nuclear translocation. Similar results were obtained when nuclear translocation of NF-κB was determined by confocal microscopy in formalin-fixed brain sections (Fig. 7c) , which showed a significant accumulation of NF-κB around 4,6-diamidino-phenylindole-stained nuclei in prion-vehicle group animals (group A), and to a lesser extent in prion-FK506 early (group B) and prion-FK506 late (group C) group animals. Furthermore the prion- minocycline group (group D) had dispersed NF-κB in the cytoplasm, similar to that observed in no prion-vehicle group animals (group E; Fig. 7c) , indicating a beneficial effect of minocycline in preventing prion-driven NF-κB nuclear translocation.
Minocycline Increases Cognition and Survival via CREB and BAD Phosphorylation
BAD is a proapoptotic member of the Bcl2 family of proteins known to modulate apoptosis. Dephosphorylation of BAD leads to its dissociation from scaffolding 14-3-3 proteins and subsequent interaction of BAD with and inhibition of the mitochondrial membrane-associated protein Bcl-xL or other Bcl2 family proteins, which results in the release of cytochrome c from the mitochondria, caspase activation, and neuronal apoptosis. CREB is a transcription factor that plays a critical role in synaptic function and memory formation. Inhibition of CREB translocation into the nucleus suppresses gene expression and induces synaptic dysfunction and memory loss [52] [53] [54] . To investigate the effect of minocycline on phosphorylation of BAD and CREB, 3 animals from each group were sacrificed at the time when hamsters injected with prion alone reached stage 5 of the clinical phase of the disease. The brain was collected and 1 hemisphere was kept frozen for later protein extractions and Western blotting while the other half was formalin fixed for histological analysis. Western blot analysis of 2 representative animals per group is depicted in Fig. 7 , and showed that there is a significant difference in the levels of pBAD and pCREB in the prion-vehicle group (group A) that is partially alleviated by treatment with minocycline or FK506, with minocycline being more effective than FK506 (Fig. 8a-d) .
Further investigation of cell degeneration was conducted by determining lamin A/C immunohistochemical staining in brain sections. A significantly higher number of lamin A/Cpositive cells were observed in prion-FK506 late treatment animals (group C) compared with other infected groups. Animals in the prion-vehicle group (group A) had the fewest lamin A/C-positive cells, almost half of the positive cells seen in the prion-FK506 early (group B) and prion-minocycline group (group C) animals (Fig. 8e, f) The no prion-vehicle group (group E) had the highest number of lamin A/Cpositive cells, showing effective, albeit incomplete, protection afforded by all treatments.
Discussion
TSEs are a group of terminal neurodegenerative disorders characterized by progressive deterioration and motor paralysis, leading to complete disability in affected humans and animals [3] . Currently, there is no effective treatment for prion diseases, despite the extensive research effort that has been devoted to this disorder over the last several years [3, 7] . The accumulation of misfolded β-sheet-rich PrP Sc in the ER, leading to ER stress, is the central event in all TSEs. Sustained long-term ER stress leads to early neurodegenerative anomalies such as synaptic dysfunction, hampered axonal transport, neuroinflammation, followed by neuronal degeneration and, ultimately, apoptosis. The continuous conversion of nontoxic α-sheet-rich cellular prion (PrP c ) to highly neurotoxic β-sheet-rich scrapie prion (PrP Sc ) makes it difficult to develop an effective therapy for prion diseases. Accordingly, there is ample consensus that the most effective therapeutic strategy would be a combinatory approach based on stopping the conversion of cellular PrP c into the neurotoxic PrP Sc , on the one hand, while rescuing neurons from early synaptic dysfunction and neuroinflammation to later neurodegeneration and apoptosis on the other. Sc levels in in vitro models and increasing survival in in vivo models of prion diseases [55] , no effective treatment is yet available for prion diseases, partly owing to the fact that many of these compounds either cannot cross the blood-brain barrier or cause severe toxic effects [56] . Our treatment approach was based on targeting either misfolded prion proteins or their downstream signaling to prevent early synaptic dysfunction, neuroinflammation, and neurodegeneration, both in the presymptomatic and symptomatic phases of prion disease. Our data showed that accumulation of misfolded PrP Sc leads to ER stress-mediated alterations in calcium homeostasis and hyperactivation of CaN, a Ca 2+ /calmodulin-dependent serine/ threonine protein phosphatase that has been implicated in Tcell activation through the induction of NFAT [8, 21, 57] .
These data thus suggest that downregulation of CaN activity might be a promising therapeutic target for prion diseases. This possibility is further encouraged by the fact that effective and well-characterized CaN inhibitors such as tacrolimus (FK506) or ciclosporin are available and approved for clinical use in humans [1, 58] .
Neuroinflammation is an important target for early therapeutic intervention in prion diseases. Minocycline, a tetracycline derivative, has potent anti-inflammatory, antiapoptotic, and neuroprotective properties [59] . Minocycline was chosen here not only because of its safety and blood-brain barrier crossing potential, but also for its reported plaque-reducing effects in AD and atherosclerotic models [60, 61] .
Our results showed a significantly beneficial effect of minocycline on prion-driven behavioral abnormalities compared with FK506 treatment. We observed intact nesting behavior for the first 2 months postinfection in all experimental groups, except the prion-vehicle group (group A) that showed impaired nesting behavior by the second month compared with the no prion-vehicle animals (group E). By the third month, the impairment in nesting behavior of prion-vehicle animals (group A) was further exacerbated and was completely rescued by minocycline treatment (Fig. 1b) . We observed that nesting behavior was directly proportional to the extent of disease progression and as the prion-vehicle (group A) and prion-FK506 early (group B) group animals did not show prolonged survival, their nesting behavior declined quickly compared with the prion-minocycline group. Other behavioral tests, including motor activity, rearing, novel object finding, exploring time, and average distance covered in an open-field test also showed significant differences between the minocycline and FK506-treated animals in that minocycline counteracted the behavioral deficits induced by prion infection, whereas FK506 was ineffective (Fig. 1c, d ). Our results of better cognition and memory in animals in the prion-minocycline group (group D) are in accordance with previous reports [12, 14, 16, 62] . Interestingly, our data showed that reduced CaN activity in the FK506 early or late treatment groups (groups B and C, respectively) and minocycline group (group D) were independent of PrP Sc levels in prion-infected hamsters, as illustrated by the fact that accumulation of the misfolded protein in the brain of prionvehicle group (group A) animals was similar to those in the prion-minocycline (group D) and prion-FK506 groups (groups B and C). De Luigi et al. [29] have previously shown the beneficial effects of tetracycline, doxycycline and minocycline in hamsters infected with the 263 K strain of prion, either intramuscularly or subcutaneously. A single intramuscular dose of doxycycline 1 h after infection in the same site of inoculation prolonged median survival by 64%. Intraperitoneal doses of tetracyclines every 2 days for 40 or 44 days increased survival time by 25% (doxycycline), 32% (tetracycline), and 81% (minocycline) after intramuscular infection, and 35% (doxycycline) after subcutaneous infection. Our results of prolonged survival are consistent with the work of De Luigi et al. [29] : we found better results in infection of 263 K strain and subsequent treatment via the i.p. route. Overall, our findings on minocycline-treated animals are also consistent with previous work by Noble et al. [59] in AD models, and by Shahzad et al. [63] in atherosclerosis models, whereas our findings in FK506-treated animals are consistent with the work by Mukherjee et al. [3] in a prion-infected mice model where they showed no change in PrP Sc level after FK506 treatment.
Inflammation is a common event in several neurodegenerative diseases and has been recently implicated as a key mechanism responsible for the progressive nature of these disorders. As such, controlling inflammation is regarded as a possible effective therapeutic approach [13, 28] . Consistent with previous reports [3, 28] , our data showed a significant increase in astrocyte activation in prion-vehicle animals (group A) compared with the control group (group E) and further reveal that this phenomenon can be prevented by minocycline or FK506 treatment. Microglia, the brain innate immune cells, are activated in response to the accumulation of misfolded proteins resulting in neuroinflammation and subsequent neurodegeneration [13] . Our results showed a significant suppression of microglial activation in both the prion-minocycline (group D) and prion-FK506 late (group C) groups, indicating a beneficial effects of both drugs. These results are in accordance with the previous works showing anti-inflammatory functions of minocycline and FK506 in unrelated in vitro and in vivo models [13, [64] [65] [66] [67] [68] .
The neuroprotective effect of a test treatment is ultimately assessed either by direct measurement of the number of living neurons or indirectly by measuring the number of degenerating neurons. Our results showed that hamsters in the prion-minocycline group (group D) and the prion-FK506 late group (group C) had more living neurons and fewer degenerating neurons in their CNS than both prionvehicle and prion-FK506 early treatment groups (groups A and B, respectively). The observed neuroprotective effect of FK506 late treatment is consistent with previous work describing effective protection of neurons by FK506 after the appearance of clinical signs in prion-infected mice [1, 3] . We observed a progressive decline in body weight after 3 weeks of treatment in the prion-FK506 early treatment animal group (group B), even when half of the recommended dose was used. These finding suggests possible cytotoxicity due to prolonged treatment of FK506 in young animals [63, 69, 70] . The protective role of minocycline on prion-induced neurological dysfunction observed in our study is novel. Further, minocycline appears to be safe in comparison with FK506 as it did not affect body weight in treated animals. However, the survival of animals receiving minocycline after the appearance of clinical signs did not differ from that of animals in the prion-vehicle and prion-FK506 early groups (groups A and B, respectively), suggesting that late treatment with minocycline may be ineffective (data not shown). These findings suggest that the mechanisms of protection from prion with minocycline may involve reducing early neuroinflammation and subsequent neurodegeneration, which would be consistent with previous literature evidence [28, 64, 71, 72] .
Recent studies have indicated a key role of the MAPK pathway in neuroinflammation and axonal degeneration [65, 73] . Microglial activation leads to an increase of proinflammatory cytokines such as IL-1β and TNF-α via the MAPK cascade [65, 74] . Our results showed higher levels of IL-1β and TNF-α in the prion-vehicle group (group A) than in the minocycline and FK506-treated groups. MAPK p38 expression was also elevated in the prion-vehicle group (group A) compared with the other treatment groups. These data suggest that minocycline and FK506 both reduce neuroinflammation via the MAPK pathway, which is also in line with previous reports [43, 65, 66, 75] . Minocycline treatment was comparatively better then FK506 treatment in reducing neuroinflammation and this could be one possible reason for prolonged survival in the prion-minocycline group (group D). Caspasemediated apoptotic signaling has been well documented in prion and other neurodegenerative diseases [47, 48, 50, 76] . Our data showed significantly elevated caspase-12, caspase-9, and caspase-3 levels in the prion-vehicle group (group A) compared with the minocycline (group D) and FK506-treated groups (groups B and C). While these data confirmed the occurrence of a caspase-mediated apoptotic cascade in prion diseases, they also showed that this neurodegenerative phenomenon is effectively blocked by the minocycline and FK506 treatments. These results are in accordance with previous work in other systems reporting caspase inhibition by FK506 and minocycline [77] [78] [79] [80] [81] .
Activation of proinflammatory mediators by the transcription factor NF-κB is a primary event in inflammation [4, 43] . Here we showed by Western blot analysis of representative cytoplasmic and nuclear extracts obtained from brain homogenates that animals in the prion-vehicle group (group A) had a significantly higher amount of NF-κB in nuclei compared with the minocycline-(group D) and FK506-treated groups (groups B and C; Fig. 7b ). Further analysis of NF-κB nuclear localization using confocal microscopy showed a significantly higher amount of NF-κB protein clustering around nuclei in the prion-vehicle group (group A), and to a lesser extent in the prion-FK506 early (group B) and prion-FK506 late (group C) groups. However, animals in the prion-minocycline group (group D) showed the least amount of nuclear translocation of NF-κB (Fig. 7c) , which is consistent with previous reports showing reduced nuclear translocation of NF-κB induced by minocycline and FK506 [8, 65, 82] .
When we determined the effect of minocycline and FK506 treatment on known downstream targets of hyperactivated CaN, such as pCREB and pBAD, we found that the decrease in pCREB and pBAD induced by prion was effectively prevented by both minocycline and FK506, with the treatment with FK506 administered after the appearance of the clinical signs being more effective than FK506 given during the preclinical phase of prion infection (Fig. 8c, d) . The neuroprotective effect of minocycline and FK506 was further confirmed by immunohistochemical analysis of apoptotic cells using lamin A/ C staining. We observed a higher number of surviving neural cells in animals treated with FK506 and minocycline compared with those in the prion-vehicle group (group A). These results are also in accordance with previously published work showing protection of minocycline in AD and stroke animal models and of FK506 in prion models [3, 83, 84] .
In conclusion, we have shown here for the first time that minocycline, given during the presymptomatic phase of prion infection, effectively protects from all of the neurodegenerative events and behavioral deficits that are normally associated with the clinical manifestation of prion in hamsters. We further confirmed, in a hamster model of prion disease, the effectiveness of FK506 treatment given after the appearance of clinical signs. Taken together, our results suggest that both minocycline and FK506 should be considered for clinical development of a combinatory therapeutic strategy that effectively counteracts the detrimental outcomes of prion infections during both the preclinical and clinical phases of the disease.
